Using PDX models of triple-negative breast cancer (TNBC), one study found that dinaciclib, a pan-CDK inhibitor15, enhanced the anticancer efficacy of veliparib (PARPi) by inhibiting CDK12, and a phase I clinical trial of this combination for breast cancer is underway (NCT01434316)16. This evidence concerns the gene CDK12 and breast cancer.